Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Gender-Affirming Surgeries Increasingly Covered by Private Insurance, Medicare, Medicaid
March 2nd 2018Since 2000, the number of patients undergoing gender-affirming surgery who identified as self-payers decreased. From 2012-2013 to 2014, coverage by Medicare and Medicaid of gender-affirming surgeries increased 3-fold.
COPD More Prevalent in Rural Areas, CDC Analysis Finds
March 1st 2018State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
February 28th 2018New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Early Results From Clinical Trials of Chronic Conditions Are Often Exaggerated
February 22nd 2018Clinical and policy decisions made using early trial results could be misguided, according to a study that found early results in chronic disease trials are often exaggerated compared with findings in subsequent trials.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Working Paper Identifies Hospital Cost Shifting Resulting From Medicare Penalties
February 17th 2018A new National Bureau of Economic Research working paper identified potential hospital cost shifting and that hospitals penalized by the Hospital Readmission Reduction Program and the Hospital Value-Based Purchasing Program actually had an increase in average payments of 1.5%.
Discussing the Ethics of Hospital Markups With Dr Martin Makary
February 16th 2018In a new letter published in the February issue of The American Journal of Managed Care®, Martin Makary, MD, a professor of surgery at Johns Hopkins University, and his coauthors assessed price markup variation by hospital and by oncology specialty to better understand the financial hardships patients can face when charges for the same service vary widely across hospitals.
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity
February 10th 2018Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
Senate, House Pass Spending Bill With Health Program Funding After Brief Shutdown
February 9th 2018After a brief shutdown in the dead of night, the Senate passed a spending bill, which was the result of a deal reached by Republicans and Democrats to fund military and domestic programs for 2 years. The House passed the bill shortly after.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
February 9th 2018A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Shifting Hospital Care to the Home Improved Quality of Life for Patients With COPD
January 30th 2018Shifting care for patients with chronic obstructive pulmonary disease (COPD) from the hospital to the home reduced hospital readmissions by 64% and emergency department visits by 52%, a Canadian program found.
Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer
January 27th 2018Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM
January 22nd 2018The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20th 2018Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.
VA Won't Research Medical Marijuana for Chronic Pain or PTSD Among Veterans
January 17th 2018An inquiry by 10 Democrats on the House Committee on Veterans’ Affairs into whether or not the Department of Veterans Affairs (VA) would research medical marijuana in veterans suffering from posttraumatic stress disorder (PTSD) and chronic pain was met with denial.
Express Scripts Is Built for the Future of Healthcare, Says CEO Wentworth
January 10th 2018It’s true, pharmacy benefit managers (PBMs) are complicated, admitted Tim Wentworth, president and CEO of Express Scripts, during his presentation at the JP Morgan Healthcare Conference in San Francisco, California. However, the company is built to succeed in the future of healthcare, he said.
Gates Discusses the Hope of Using Immuno-Oncology for HIV Breakthroughs, and More
January 9th 2018While public funding through the National Institutes of Health has created a foundation for healthcare research, the private sector can benefit from getting more involved, said Bill Gates, philanthropist and co-founder of Microsoft.